Purple Biotech shares are trading higher after the company announced additional interim data from its randomized Phase 2 pancreatic cancer study. Also, the company said the concordant and consistent improvement in primary and all secondary endpoints including are compelling.
$PPBT
Biotechnology: Pharmaceutical Preparations
Health Care
Purple Biotech shares are trading higher after the company announced additional interim data from its randomized Phase 2 pancreatic cancer study. Also, the company said the concordant and consistent improvement in primary and all secondary endpoints including are compelling.